Docosahexaenoic Acid

How high can high-end omega-3 go?

Special edition: Omega-3 (Editor's blog)

How high can high-end omega-3 go?


Just got off the phone to Ola Snove, the new(ish) CEO of Aker part-owned Norwegian omega-3 specialist Epax. Wanted to know his view on high-end omega-3 prospects that have attracted BASF and DSM to the sector. His word: “Stellar”.

ONC is strong in omega-3 supplements, but could drug apps hold greater promise?

DSM eyes generic omega-3 drug space with €420m ONC buy

By Shane Starling

DSM will use its global reach to drive its latest acquisition - fish-sourced omega-3 leader, Ocean Nutrition Canada, beyond its core North American market – but sees opportunities in generic drugs that may prove more lucrative.

GOED explains its “big plans” for omega-3 health claims in 2012

Dispatches from SupplySide West 2011

GOED explains its “big plans” for omega-3 health claims in 2012

By Shane Starling from Las Vegas

With the volume of omega-3 science tripling in 10 years, the world’s leading omega-3 trade group is working with international regulators to have that research reflected in authorised claims – especially in the EU and the US.

US military: Low omega-3 levels may boost suicide risk

Special edition: Omega-3

US military: Low omega-3 levels may boost suicide risk

By Stephen Daniells

US troops and service personnel with low levels of omega-3 are at increased risk of suicide, says a new study that potential opens the door to widespread omega-3 supplementation.

Ayers: 360 days of sunlight

New entrant set to shake up algal omega-3 market

By Elaine Watson

A new player is poised to enter the vegetarian omega-3 market with a production process it claims will enable it to make the long chain fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from algae at a fraction of the cost of rivals.

Martek: Onwards and upwards under new ownership

Martek predicts double-digit rise in sales to food & bev market

By Elaine Watson

Martek expects sales of its algal-sourced omega-3s to food and drink manufacturers to grow in the double-digits each year for the next four to five years as it broadens its product range and gains access to new markets and customers post its takeover...

Martek is now a fullly-owned DSM subsidiary

DSM begins Martek integration

By Shane Starling

Royal DSM has kicked the integration of its new €800m wholly-owned subsidiary, Martek Biosciences Corporation, into life by establishing a special integration unit to manage the US-Dutch-Swiss deal.


Follow us


View more


Featured Suppliers